REN and cardiac hypertrophy: In contrast, older studies looking at the effectiveness of renin-angiotensin-aldosterone inhibitors did not exclude these categories of cardiovascular disease with poor prognosis because the initial concept of the pathophysiological mechanism of HFpEF considered primary cardiac injury manifested by ventricular hypertrophy and diastolic dysfunction as the primary cause of HFpEF syndrome [23].